Determination of amikacin stability at 1% and 3% concentrations in four topical solutions over a 56-day period.

BACKGROUND: Anecdotally, amikacin has been added to compounded topical preparations for the management of canine bacterial otitis externa. However, the stability of amikacin within these solutions is unknown. HYPOTHESIS/OBJECTIVES: The purpose of this study was to determine the stability of amikacin at 10 and 30 mg/mL concentrations in four topical solutions over a 56 day period. We hypothesised that amikacin would maintain chemical stability within the various solutions. METHODS AND MATERIALS: Amikacin was formulated to 10 and 30 mg/mL (1% and 3%) concentrations within four topical solutions: tris-EDTA (TrizEDTA Aqueous Flush) (TE); 0.15% chlorhexidine gluconate and tris-EDTA (TrizCHLOR Flush) (TC); 0.9% NaCl (NA); and 0.9% NaCl + 2 mg/mL dexamethasone (ND). Samples were made in duplicate and stored at room temperature (25°C) for 0, 7,14, 21, 28 and 56 days. Amikacin content was quantified, in triplicate, by ultrahigh-performance liquid chromatography tandem mass spectrometry. RESULTS: The recovered amikacin concentrations for the 10 mg/mL solutions ranged from 10 to 13.5 mg/mL (mean 11.5 mg/mL) with the exception of NA sample 2 at Day (D)0 (9.4 mg/mL) and D7 (9.2 mg/mL). The recovered amikacin concentrations for the 30 mg/mL solutions ranged from 30 to 40.2 mg/mL (mean 35.7 mg/mL). No significant difference was seen between the amikacin concentrations at D0 compared to D56 for all solutions except 10 mg/mL TE (P < 0.001). CONCLUSIONS AND CLINICAL RELEVANCE: Amikacin maintained stability within TE, TC, NA and ND over 56 days except when formulated at 10 mg/mL within TE.

Wearable sensor shown to specifically quantify pruritic behaviors in dogs.

BACKGROUND: Wearable technology is an exciting new field in humans and animals. In dogs activity monitors have helped to provide objective measurement tools where pet owner observation had been the only source of information. Previous research has focused on measuring overall activity versus rest. This has been relatively useful in determining changes in activity in orthopedic disease or post-surgical cases [Malek et al., BMC Vet Res 8:185, 2012, Yashari et al., BMC Vet Res 11:146, 2015]. Assessment of pruritus via changes in activity, however, requires an assumption that increased activity is due to scratching or other pruritic behaviors. This is an inaccurate method with obvious flaws as other behaviors may also register as greater activity. The objective of this study was to validate the ability of a multidimensional high frequency sensor and advanced computer analysis system, (Vetrax®, AgLogica Holdings, Inc., Norcross, GA, USA) to specifically identify pruritic behaviors (scratching and head shaking). To establish differences between behaviors, sensor and time stamped video data were collected from 361 normal and pruritic dogs. Video annotations were made by two observers independently, while blinded to sensor data, and then evaluated for agreement. Annotations that agreed between the two were used for further analysis. The annotations specified behaviors at specific times in order to compare with sensor data. A computer algorithm was developed to interpret and differentiate between these behaviors. Test subject data was then utilized to test and score the system's ability to accurately predict behaviors. RESULTS: Results for prediction of head shaking behavior included sensitivity and specificity of 72.16% and 99.78% respectively. Analysis of scratching produced sensitivity and specificity of 76.85% and 99.73% respectively. These results illustrate the ability of the system to accurately report both scratching and head shaking with an overall accuracy of 99.24% and 99.56% respectively. CONCLUSIONS: This study validates the use of this system to accurately and objectively report scratching and head shaking in dogs. While a small portion of scratching or head shaking behaviors may be missed, as indicated by the sensitivity, when detected, the confidence that these behaviors occurred is extremely high. These factors make this system a very useful tool for objective assessment of pruritus in clinical and research settings.

Old or new? A comparison of mitotane and trilostane for the management of hyperadrenocorticism.

Hyperadrenocorticism (HAC) is a common endocrinopathy in dogs. With better recognition of the disease, more cases are being presented to clinicians for management. Mitotane, a 3- to 4-decade-old therapy, remains a viable and useful option for management of this disease. Thorough education and understanding of the drug are important, however, as the learning curve of how to manage its effects can be significant. Trilostane, a newer option for management of HAC, offers a simplified protocol and, often, smoother and faster control of the disease. It also requires a comfortable knowledge of expected outcome and possible adverse effects. With either drug, careful monitoring and client communication are crucial.

Owner assessment of therapeutic interventions for canine atopic dermatitis: a long-term retrospective analysis.

BACKGROUND: Canine atopic dermatitis is a frequent diagnosis in veterinary medicine; however, the long-term prognosis for canine atopic dermatitis has not been evaluated in a systematic fashion. HYPOTHESIS/OBJECTIVES: To compare the relative efficacy of commonly used therapies for canine atopic dermatitis in two groups of dogs over 5 and 10 year time periods. ANIMALS: Dogs were identified from the medical record database of a privately owned veterinary dermatology practice in the USA. METHODS: Clients completed a four-part, 28-question, Internet-based survey. Surveys were included in the analysis if one entire section was completed. Each question was completed independently of the answers to other questions. RESULTS: Several respondents failed to complete all questions. Some respondents answered similar questions with contradictory answers. Each question was analysed individually. A total of 136 owner surveys were completed, 39 from the 10 year and 97 from the 5 year study dogs. Eighty-five of 135 respondents indicated that their pet was receiving some form of medical therapy for atopic dermatitis at the time of the survey. Thirty of 90 respondents (33.3%) indicated that their dog improved during a dietary trial. Five dogs met the study's definition for clinical cure. All five of these dogs had been treated with allergen-specific immunotherapy. CONCLUSIONS AND CLINICAL IMPORTANCE: This study revealed that clients believe antihistamines can be a useful part of multimodal therapy for canine atopic dermatitis. The results also demonstrated that a significant number of canines benefited from dietary modification. In addition, allergen-specific immunotherapy was the only treatment to induce true clinical remission of atopic dermatitis.

Topical 0.1% tacrolimus for the treatment of discoid lupus erythematosus and pemphigus erythematosus in dogs.

Topical 0.1% tacrolimus was used for treatment of localized lesions associated with 10 cases of discoid lupus erythematosus (DLE) and two cases of pemphigus erythematosus (PE) either as a sole therapy (n=2) or as an adjunctive treatment (n=10). Eight of 10 dogs with DLE and both dogs with PE were improved following 8 weeks of topical application. In six of the eight dogs that improved, other medications were discontinued. No adverse effects in clinical or laboratory parameters were noted throughout the study.